GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Deinove SA (XPAR:ALDEI) » Definitions » Debt-to-EBITDA

Deinove (XPAR:ALDEI) Debt-to-EBITDA : -0.84 (As of Jun. 2022)


View and export this data going back to 2010. Start your Free Trial

What is Deinove Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Deinove's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was €1.43 Mil. Deinove's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was €4.85 Mil. Deinove's annualized EBITDA for the quarter that ended in Jun. 2022 was €-7.50 Mil. Deinove's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 was -0.84.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Deinove's Debt-to-EBITDA or its related term are showing as below:

XPAR:ALDEI's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.36
* Ranked among companies with meaningful Debt-to-EBITDA only.

Deinove Debt-to-EBITDA Historical Data

The historical data trend for Deinove's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deinove Debt-to-EBITDA Chart

Deinove Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.08 -0.04 -0.13 -0.46 -0.92

Deinove Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.18 -0.57 -0.51 -0.89 -0.84

Competitive Comparison of Deinove's Debt-to-EBITDA

For the Biotechnology subindustry, Deinove's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Deinove's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Deinove's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Deinove's Debt-to-EBITDA falls into.



Deinove Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Deinove's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.634 + 4.688) / -6.891
=-0.92

Deinove's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.43 + 4.852) / -7.496
=-0.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2022) EBITDA data.


Deinove  (XPAR:ALDEI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Deinove Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Deinove's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Deinove (XPAR:ALDEI) Business Description

Traded in Other Exchanges
N/A
Address
1682 rue de la Valsiere, Cap Sigma, ZAC Euromedecine II, Grabels, FRA, 34790
Deinove SA is a biotechnology company engaged in the development of technologies and molecules for the health, nutrition and cosmetics industries. It is developing in two areas of activity, New-generation anti-infective ANTIBIOTICS which involves the search for novel anti-infective molecules and the development of new generations of drugs capable of responding to the challenges of antibiotic resistance; and BIOACTIVES, natural active ingredients discovers, develops and produces bioactives, active ingredients of natural origin from its bacterial biodiversity bank, to invent the new generation of sustainable cosmetics and intends to quickly bring its know-how and its products to other fields, such as nutrition and health.

Deinove (XPAR:ALDEI) Headlines

No Headlines